MicroPort® Wins the Award of Top 10 Pudong Headquarters Economy Classic Samples

Shanghai, China – The award ceremony of the fifth edition of Top 10 Pudong Headquarters Economy Classic Samples was held at the Shanghai International Convention Center on February 20, unveiling the final results for the annual top 10 classic samples of the headquarters economy and two individual awards. Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) won the award of top 10 classic samples.

Pudong New Area Deputy Head Mr. Hua Wang said in a speech that the Pudong New Area has gathered over 600 headquarters of various kinds of enterprises by far, which has become a powerful engine for Pudong’s high quality development. The development and achievements of Pudong’s economy would not have been possible without the efforts of the headquarters of both domestic and overseas enterprises, especially the outstanding headquarters of the domestic and overseas enterprises emerging in the fifth edition of Top 10 Pudong Headquarters Economy Classic Samples. Almost all of them are leaders in their respective areas, showing that Pudong’s headquarters economy is generally in full swing and continues to develop to a higher level, with broader coverage and more content.

MicroPort® Chief Finance Officer Mr. Martin Sun attended the award ceremony and said in a news media interview: “MicroPort® was founded as a start-up by the people who studied abroad. MicroPort® has been growing together with Pudong. The commitment of Pudong government as a service provider deserves our compliment in that MicroPort® has grown to a medical device corporation with a global reach from a small-size enterprise. The Top 10 Classic Samples award came as recognition and encouragement to us. MicroPort® will work with the authorities to jointly promote the economic growth and industrial development of Pudong. With our efforts, we hope that we can develop the medical technology epitomizing the world’s cutting-edge technology to bring health and longevity to every corner, community, family and patient of the world in the fairer and more equitable way.”

Established in 1998 and after 20 years’ development, MicroPort® has become a multinational medical device group comprised of dozens of subsidiary entities. With its headquarters in the Pudong Zhangjiang Science City in Shanghai, China, MicroPort® possesses a large footprint of major manufacturing and R&D facilities across the world, including Shanghai, Suzhou, Jiaxing, Dongguan in China, Memphis in the United States, Clamart in France, Saluggia in Italy, and the Dominican Republic, creating a globalized network of R&D, manufacturing, marketing, and services. Thus far, MicroPort® has released about 300 products to the market, covering 10 major business segments, including interventional cardiology and structural heart, cardiac rhythm management and electrophysiology, orthopedics, endovascular, neurovascular and neuro science, diabetes and endocrine management, urology and women’s health, general surgery, surgical robotics, and artificial intelligence. As of the end of 2018, the MicroPort® products have entered over 8,000 hospitals globally, covering Asia Pacific, Europe, and the Americas. We estimate that every 12 seconds a patient is being implanted with a MicroPort® manufactured device to save a life, improve the quality of a life, or create a new life.